bioRxivMicrobiologyPreprint
Spike antibodies targeting GRP78 predispose to cardiovascular complications compared to Dengue
Supratim SarkeriD, Trina RoyiD, Abinash MallickiD, S. K. Das, Sarakam Dharma Teja, Arun BandyopadhyayiD, Abhishek DeiD, Surajit GoraiiD, Subhajit BiswasiD
Abstract
One major aftermath of COVID-19 pandemic is cardiovascular consequences. SARS-CoV-2 binds to ACE2 and downregulates vasodilation. Dengue favors hypotension by weakening endothelial glycocalyx leading to plasma leakage. C1q levels, immune complexes (ICs), and proteomic profiles in serum samples from 52 COVID-19 and 19 pre-pandemic Dengue cases were studied. Unlike Dengue, COVID-19 serums showed elevated coagulation proteins promoting vaso-occlusion and peripheral artery diseases. The stress-induced chaperone and atherosclerosis marker, GRP78 (gene/ protein) was found upregulated upon SARS-CoV-2 spike expression in cardiac/ lung cell lines. Elevated GRP78 levels were also observed in serum samples from COVID-19-diagnosed individuals and subjects with myocardial infarction (MI) in post COVID-era. Surprisingly, spike antibodies (Abs) showed cross-binding to GRP78 and possibly contributed to the observed higher-level ICs in COVID-19 serums (cardiovascular embolism?). Co-localization studies showed that spike Abs (analogous to pro-atherosclerotic GRP78 auto-Abs) could directly bind to upregulated cellular GRP78 (type II hypersensitivity?). Both pathways could worsen vascular injury and atherosclerosis, leading to cardiac complications in COVID-19 cases with narrowed vessels.
- organism: human
- assay: proteomics
- research focus: host-pathogen & immune response
- approach: experimental assay
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- SARS-CoV-2 spike antibodies cross-react with dengue virus and enhance infection in vitro and in vivo
- The SARS-CoV-2 Spike protein disrupts human cardiac pericytes function through CD147-receptor-mediated signalling: a potential non-infective mechanism of COVID-19 microvascular disease
E. Avolio, M. Carrabba, … P. Madeddu·Clinical SciencePeer-reviewed·Dec 15, 2021
- Pericyte-specific vascular expression of SARS-CoV-2 receptor ACE2 - implications for microvascular inflammation and hypercoagulopathy in COVID-19
L. He, M. A. Mae, … C. Betsholtz·bioRxiv·May 11, 2020
- Selectively expressing SARS-CoV-2 Spike protein S1 subunit in cardiomyocytes induces cardiac hypertrophy in mice.
S. G. Negron, C. W. Kessinger, … Z. Lin·bioRxiv·Jun 20, 2021
- Common cardiac medications potently inhibit ACE2 binding to the SARS-CoV-2 Spike, and block virus penetration into human lung cells
H. Caohuy, O. Eidelman, … H. B. Pollard·bioRxiv·Jun 2, 2021
- SARS-CoV-2 spike protein induces brain pericyte immunoreactivity in absence of productive viral infection
Rayan Khaddaj‐Mallat, Natija Aldib, … Ayman ElAli·bioRxiv·Apr 30, 2021